Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5249920 | 0.92 | ALDH1A1 (0.42) | ALDH1A1POLBKMT2AKDM4EMAPT | |
| SCHEMBL4467393 | 0.92 | PDE4B (0.43) | RAB9ANPC1WNT3A | |
| SCHEMBL4471609 | 0.92 | KMT2A (0.40) | ALDH1A1POLBKMT2AKDM4EMAPT | |
| SCHEMBL4460922 | 0.91 | KMT2A (0.46) | ALDH1A1POLBKMT2AKDM4EMAPT | |
| SCHEMBL28772969 | 0.90 | KMT2A (0.40) | ALDH1A1POLBKMT2AKDM4EMAPT | |
| SCHEMBL5249919 | 0.89 | ALDH1A1 (0.40) | ALDH1A1POLBKMT2AKDM4EMAPT | |
| SCHEMBL8268620 | 0.88 | ALDH1A1 (0.42) | ALDH1A1POLBKMT2AKDM4EMAPT | |
| SCHEMBL4462219 | 0.85 | SMN1; SMN2 (0.38) | ALDH1A1KMT2AMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL4461479 | 0.85 | JAK2 (0.35) | POLBKMT2AKDM4ERAB9ANPC1 | |
| SCHEMBL4465348 | 0.83 | KMT2A (0.45) | ALDH1A1KMT2AMAPTSMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585882-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-09-08 | — | — | US | claimed |
| CN-101166737-A | Phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2008-04-23 | — | — | CN | claimed |
| EP-1802615-A1 | PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2007-07-04 | — | — | EP | claimed |
| US-20060135535-A1 | 4-(substituted-phenyl)-2-pyrrolidinones; reduced emetic side effects; antiinflammatory agents; neurological syndromes, asthma, arthritis | MEMORY PHARMACEUTICALS CORPORATION | 2006-06-22 | — | — | US | claimed |
| WO-2006044955-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | claimed |
| US-20090306156-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2009-12-10 | — | — | US | disclosed |
| US-20090306156-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2009-12-10 | — | — | US | disclosed |
| US-20090306156-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2009-12-10 | — | — | US | disclosed |
| US-7585882-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585882-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585882-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-09-08 | — | — | US | disclosed |
| WO-2009067607-A2 | COMBINATIONS OF PDE4 INHIBITORS AND ANTIPSYCHOTICS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-05-28 | — | — | WO | disclosed |
| CN-101166737-A | Phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2008-04-23 | — | — | CN | disclosed |
| EP-1802615-A1 | PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2007-07-04 | — | — | EP | disclosed |
| US-20060135535-A1 | 4-(substituted-phenyl)-2-pyrrolidinones; reduced emetic side effects; antiinflammatory agents; neurological syndromes, asthma, arthritis | MEMORY PHARMACEUTICALS CORPORATION | 2006-06-22 | — | — | US | disclosed |
| WO-2006044955-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006044955-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135535-A1 | 4-(substituted-phenyl)-2-pyrrolidinones; reduced emetic side effects; antiinflammatory agents; neurological syndromes, asthma, arthritis | PDE4A, PDE4B, PDE12 | ALDH1A1 448/4885POLB 1746/4885KMT2A 1797/4885 |
| US-20090306156-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE5A | ALDH1A1 395/4885POLB 1089/4885KMT2A 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.